Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31451925 | 0.91 | CTSK (0.42) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL2798365 | 0.88 | USP2 (0.43) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL23071129 | 0.88 | USP2 (0.45) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL17830842 | 0.88 | USP2 (0.45) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL10529377 | 0.87 | USP2 (0.44) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL20571615 | 0.87 | USP2 (0.44) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL17176669 | 0.87 | JAK2 (0.44) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL23283111 | 0.87 | USP2 (0.44) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL21325460 | 0.86 | CYP4F2 (0.43) | USP2SMN1; SMN2CTSKMEN1KMT2A | |
| SCHEMBL28709409 | 0.85 | USP2 (0.43) | USP2SMN1; SMN2CTSKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652159-A1 | INHIBITORS OF KIF18A AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-11-26 | — | — | EP | disclosed |
| US-20250340569-A1 | INHIBITORS OF KIF18A AND USES THEREOF | INSILICO MEDICINE IP LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-12441704-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| EP-4620533-A2 | ANTAGONIST COMPOUNDS | Adorx therapeutics Limited (GB) | 2025-09-24 | — | — | EP | disclosed |
| US-20250206745-A1 | PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-06-26 | — | — | US | disclosed |
| WO-2025124415-A1 | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS | NIKANG THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025123318-A1 | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2025-06-19 | — | — | WO | disclosed |
| EP-4188924-B1 | ANTAGONIST COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-06-18 | — | — | EP | disclosed |
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025051241-A1 | MACROCYCLIC COMPOUND AND ANTIBODY-DRUG CONJUGATE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-7915274-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | OZAKI FUMIHIRO | 2007-12-20 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| EP-1484327-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | EISAI R&D MAN CO LTD (JP) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007030061-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
| US-6995144-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1484327-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | USP2 3639/4885SMN1; SMN2 1451/4885CTSK 3787/4885 |
| US-20250340569-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF2C | USP2 1987/4885SMN1; SMN2 81/4885CTSK 1717/4885 |
| US-20250206745-A1 | PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NLRP1 | USP2 2631/4885SMN1; SMN2 4456/4885CTSK 1823/4885 |
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | CCR8, CCR1, CCR10 | USP2 1086/4885SMN1; SMN2 609/4885CTSK 4376/4885 |
| US-12441704-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | USP2 4401/4885SMN1; SMN2 4320/4885CTSK 3288/4885 |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | NQO1, CBR1, NOX1 | USP2 3522/4885SMN1; SMN2 1325/4885CTSK 4257/4885 |
| US-20050245527-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | USP2 3639/4885SMN1; SMN2 1451/4885CTSK 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.